In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 49, No. 1 ( 2005-01), p. 276-280
Abstract:
The pharmacodynamic profile of ertapenem was evaluated in a neutropenic mouse thigh infection model. Extended-spectrum beta-lactamase (ESBL)-positive and ESBL-negative clinical strains of Escherichia coli and Klebsiella pneumoniae were studied. MICs ranged from 0.0078 to 0.06 μg/ml with standard inoculum tests. Ertapenem doses were administered once to five times daily to achieve various exposures, reported as the percentage of the dosing interval that the concentration of free ertapenem was in excess of the MIC (% T 〉 MIC free ). Mean values for the static exposure and 80% maximally effective exposure (ED 80 ) were 19% (range, 2 to 38%) and 33% (range, 13 to 65%) T 〉 MIC free , respectively. Differences in exposure requirements based on the presence of an ESBL resistance mechanism or bacterial species were not evident. In addition, experiments using a 100-fold higher inoculum did not decrease the magnitude of the reduction in bacterial density from baseline achieved compared to lower-inoculum studies. The pharmacodynamic parameter of % T 〉 MIC free correlated well with bactericidal activity for all isolates, and the static and ED 80 exposures are consistent with those reported previously for carbapenems.
Type of Medium:
Online Resource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.49.1.276-280.2005
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
2005
detail.hit.zdb_id:
1496156-8
detail.hit.zdb_id:
217602-6
SSG:
12
SSG:
15,3
Permalink